發(fā)布時間：2018-05-08 05:35

  本文選題：糖尿病性黃斑水腫 + 康柏西普��； 參考：《上海交通大學學報(醫(yī)學版)》2017年05期

【摘要】：目的·評價玻璃體腔內(nèi)注射抗血管內(nèi)皮生長因子(VEGF)藥物康柏西普對治療糖尿病性黃斑水腫(DME)的臨床效果。方法·選取DME(炎癥型)患者11例17眼,每月行1次康柏西普玻璃體腔內(nèi)注射,首次治療之后按需治療。治療結(jié)束后隨診6個月以上,比較治療前后患者的最佳矯正視力(BCVA)、中央視網(wǎng)膜厚度(CRT)、DME消退率及眼底熒光血管造影檢查(FFA)結(jié)果。結(jié)果·隨訪時間為7~29個月,平均(12±7)個月。注射針數(shù)1~10針,平均針數(shù)為(4±3)針。DME患者注藥后BCVA明顯提高(t=7.306,P=0.001),CRT下降顯著(t=5.272,P=0.000),差異有統(tǒng)計學意義。DME總消退率為76.5%。結(jié)論·玻璃體腔內(nèi)注射抗VEGF藥物康柏西普,可明顯改善DME患者的視力,明顯消退黃斑水腫癥狀。
[Abstract]:Objective to evaluate the effect of intravitreal injection of anti vascular endothelial growth factor (VEGF) on diabetic macular edema (DM). Methods 11 cases (17 eyes) of DME (inflammatory type) were treated by intravitreal injection once a month. The best corrected visual acuity (BCVA), central retinal thickness (CRT), DME regression rate and fundus fluorescein angiography (FFA) were compared before and after treatment. Results the follow-up time was 7 ~ 29 months (mean 12 鹵7) months. The average number of injections was 4 鹵3). The BCVA of the patients with DME was significantly higher than that of the control group (P < 0.01). The decrease of BCVA was significant (P < 0.01). The difference was statistically significant. The total regression rate of DME was 76.5%. ConclusionIntravitreal injection of VEGF can significantly improve the visual acuity of patients with DME and attenuate the symptoms of macular edema.
【作者單位】： 上海交通大學醫(yī)學院附屬仁濟醫(yī)院眼科;上海市浦東新區(qū)陸家嘴社區(qū)衛(wèi)生服務中心眼科;上海市浦東新區(qū)公利醫(yī)院眼科;上海市浦東新區(qū)濰坊社區(qū)衛(wèi)生中心眼科;
【基金】：上海市浦東新區(qū)衛(wèi)生局衛(wèi)生(計生)科技項目(PW2013D-1) 上海市衛(wèi)生和計劃生育委員會面上項目(M20140513)~~
【分類號】：R587.2;R774
，

本文編號：1860159